Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

FOFO vs SBC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SBC Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 9–1 Matrix Metrics)

SBC Overall Winner 6-Pillar Tally: FOFO 0 – 5 SBC (1 Tie) Matrix Metrics: FOFO 1 – 9 SBC

As of Nov 20, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over Hang Feng Technology Innovation Co., Ltd. (FOFO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FOFO carries a Unified Composite Score of 43.0/100 (HOLD) at $1.50 (N/M Forward P/E, -823.6% operating margin), whereas SBC carries 47.2/100 (HOLD) at $5.17 (9.0x Forward P/E, 39.9% operating margin).

  • Technical & Structure Timing Caution: FOFO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2); meanwhile SBC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About FOFO vs SBC
FOFO NASDAQ
Hang Feng Technology Innovation Co., Ltd. Ordinary Shares
Services-Management Consulting Services
$1.50
-7.41% 1D
Market Cap $12.8M
TTM Revenue $1.4M
Forward P/E N/M
Beta / 30D Vol 0.45β · 65% Vol
Unified Composite Score
43.0 / 100 HOLD
Tech 33.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -11.8%), weak momentum, RSI 29
RSI-14: 29.2 · SMA20: $1.75 · SMA50: $1.91
SBC NASDAQ Head-to-Head Winner
SBC Medical Group Holdings Incorporated Common Stock
Services-Offices & Clinics Of Doctors Of Medicine
$5.17
-7.68% 1D
Market Cap $574.4M
TTM Revenue $190M
Forward P/E 9.0x
Beta / 30D Vol 0.96β · 159% Vol
Unified Composite Score
47.2 / 100 HOLD
Tech 41.0 Fund 36.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.2 · SMA20: $5.54 · SMA50: $5.28

6-Pillar Scorecard Institutional Category Breakdown (FOFO 0 – 5 SBC)

Columns: Metric · FOFO · SBC
1. Valuation Multiples SBC
Forward P/E N/M 9.0x
Trailing P/E N/M 11.0x
PEG Ratio N/M 2.40x
EV / Revenue 9.4x 3.0x
2. Growth & Scale SBC
Revenue Growth (YoY) -72.7% +35.1%
Earnings Growth (YoY) +0.0% +22.4%
TTM Revenue (USD) $1.4M $190M
Market Cap $12.8M $574.4M
3. Profitability & Quality SBC
Gross Margin 7.0% 72.2%
Operating Margin -823.6% 39.9%
Net Profit Margin 0.0% 27.3%
Return on Equity (ROE) -169.2% 19.3%
4. Balance Sheet & Cash Flow SBC
Cash Generation (TTM) -$11M EBITDA $80M EBITDA
Cash Flow Margin N/A 41.8% EBITDA Mgn
Net Cash / Leverage $1.02 Book/Sh · -169.2% ROE $2.79 Book/Sh · 19.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SBC
OpEx & R&D Intensity N/A 32.3% of Rev ($61M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Consulting Services Operator Consulting Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: FOFO (1) vs SBC (9)
Institutional Metric FOFO SBC Criterion Row Edge
Market Capitalization
Scale
$12.8M $574.4M Larger Scale SBC
Trailing P/E Ratio
Valuation
N/M 11.0x Lower Multiple SBC
Forward P/E Ratio
Valuation
N/M 9.0x Lower Multiple SBC
Revenue Growth (YoY)
Growth
-72.7% +35.1% Higher Growth SBC
Operating Margin (TTM)
Profitability
-823.6% 39.9% Higher Margin SBC
Net Profit Margin
Profitability
0.0% 27.3% Higher Margin SBC
Return on Equity (ROE)
Capital Efficiency
-169.2% 19.3% Higher ROE SBC
52-Week Range Position
Momentum
0% ($2–$15) 52% ($3–$7) Stronger Trend SBC
Beta / 30D Volatility
Risk Regime
0.45β · 65% Vol 0.96β · 159% Vol Lower Realized Risk FOFO
Unified Institutional Score
Composite Signal
43.0 / 100 (HOLD) 47.2 / 100 (HOLD) Higher Composite SBC
Trailing 12M Revenue (USD)
Operating Scale
$1.4M $190M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
7.0% 72.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 9.4x EV/Rev 2.40x PEG · 3.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$11M EBITDA ($1.02 Book/Sh · -169.2% ROE) $80M EBITDA ($2.79 Book/Sh · 19.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SBC +14.72 pp
FOFO: -23.86% · SBC: -9.14%
3M Horizon SBC +63.36 pp
FOFO: -38.78% · SBC: +24.58%
6M Horizon SBC +93.4 pp
FOFO: -25.0% · SBC: +68.4%
1Y Horizon SBC +149.5 pp
FOFO: -85.89% · SBC: +63.61%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on FOFO vs SBC. Trailing 12-month operating profitability (FOFO -823.6% vs SBC 39.9%) and valuation multiples (FOFO N/M vs SBC 9.0x Forward P/E) are benchmarked directly in Pillar 4 below.

FOFO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.4M
Gross Margin7.0%
Op. Margin-823.6%
ROE / Fwd P/E-169.2% · N/M
SBC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$190M
Gross Margin72.2%
Op. Margin39.9%
ROE / Fwd P/E19.3% · 9.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
FOFO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FOFO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SBC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SBC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
FOFO Moat Profile Cyclical / Execution-Driven Positioning
Consulting Services Operator
Competes within the Consulting Services value chain with $12.8M market capitalization and -823.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SBC Moat Profile High-Margin Pricing Power Moat
Consulting Services Operator
Competes within the Consulting Services value chain with $574.4M market capitalization and 39.9% operating margin.
OpEx & R&D Reinvestment 32.3% of Rev ($61M)
90D Engineering Disclosures 0 Published

Investor FAQ FOFO vs SBC Key Questions & Quantitative Answers

As of Nov 20, 2026, SBC Medical Group Holdings Incorporated (SBC) is the stronger overall head-to-head candidate over Hang Feng Technology Innovation Co., Ltd. (FOFO) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). FOFO carries a Unified Composite Score of 43.0/100 (HOLD) at $1.50 (N/M Forward P/E, -823.6% operating margin), whereas SBC carries 47.2/100 (HOLD) at $5.17 (9.0x Forward P/E, 39.9% operating margin). Technical & Structure Timing Caution: FOFO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.2); meanwhile SBC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SBC leads the Growth & Scale pillar: FOFO posts -72.7% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (7.0% gross margin, -823.6% operating margin), compared with SBC at +35.1% YoY revenue growth and +22.4% YoY earnings growth on $190M TTM revenue (72.2% gross margin, 39.9% operating margin). On trailing 12-month operating scale, FOFO generates $1.4M in USD-normalized revenue versus $190M for SBC. In operating R&D and SG&A reinvestment, FOFO deploys N/A (0 90-day corporate R&D disclosures) versus 32.3% of Rev ($61M) (0 disclosures) for SBC.

SBC screens cheaper on headline valuation multiples. FOFO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.4x EV/Revenue (unreported EBITDA margin), whereas SBC trades at 9.0x Forward P/E, 11.0x Trailing P/E, 2.40x PEG, and 3.0x EV/Revenue (41.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FOFO (-169.2% ROE) versus SBC (19.3% ROE) capital efficiency.

In options market volatility and institutional positioning, FOFO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 65% Vol realized risk). By comparison, SBC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.96β · 159% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.